Publikationen in Zusammenarbeit mit Forschern von University of Edinburgh (8)

2024

  1. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

    European Journal of Cancer, Vol. 202

2023

  1. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2998-3008

  2. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997

  3. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

2021

  1. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

    Breast Cancer Research and Treatment, Vol. 187, Núm. 1, pp. 155-165

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial

    Journal of Clinical Oncology

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390